Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Comparative Hepatobiliary and Intestinal Research Program (CHIRP), College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
J Vet Pharmacol Ther. 2024 Jul;47(4):266-273. doi: 10.1111/jvp.13439. Epub 2024 Mar 22.
Gelatin capsules deliver their contents to the stomach, while delayed-release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium-impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post-ingestion, 30 min post-ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, n = 6), increased meal size (phase 2, n = 2), double encapsulation (phase 3, n = 2), and altered capsule size (phase 4, n = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60-90) to release BIPS™ compared to gelatin capsules (15 min, range 15-30; p = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.
明胶胶囊将其内容物递送到胃中，而延迟释放（DR）胶囊旨在允许递送到小肠。本研究评估了 6 只健康成年犬的 DR 胶囊与明胶胶囊在胃肠道中的释放部位。明胶和 DR 胶囊均填充有钡浸渍的聚乙烯球（BIPS™），在口服给药后，使用腹部射线照相术在基线、摄入后立即、摄入后 15 分钟、摄入后 30 分钟以及此后每 30 分钟评估释放部位。评估的阶段包括空腹条件（第 1 阶段，n=6）、增加膳食量（第 2 阶段，n=2）、双重包封（第 3 阶段，n=2）和改变胶囊尺寸（第 4 阶段，n=1）。对于两种胶囊类型，释放部位均在所有阶段均为胃部。在第 1 阶段，与明胶胶囊（15 分钟，范围 15-30；p=0.03）相比，DR 胶囊释放 BIPS™的时间明显延长（中位数 60 分钟，范围 60-90）。在第 2 阶段（全餐量）、第 3 阶段（双重包封）和第 4 阶段（较小的胶囊尺寸）试验研究中，释放时间延长，但仍发生在胃部。这与明胶胶囊的释放部位相似，但与人体内 DR 胶囊的释放部位不同。这对受胃生理影响的产品（例如粪便微生物群移植）的药效学结果有影响。基于这些初步数据，临床医生和研究人员不应假设 DR 胶囊将允许内容物在犬体内肠道传递。应在更大和更多样化的犬群中进行未来的研究。
